COMBINATION THERAPY FOR B-CELL DISORDERS CROSS-REFERENCE TO RELATED APPLICATION [01] This application claims priority to U.S. Patent Application No.63/311,207 filed on February 17, 2022, titled “Combination Therapy For B-Cell Disorders,” which is incorporated by reference herein in its entirety. TECHNICAL FIELD [02] This disclosure relates generally to combination therapies for B-cell disorders, including cancers. BACKGROUND [03] Multiple myeloma (MM) is an incurable malignancy and accounts for 1% of all cancers and for 10% of all hematologic malignancies. A variety of drugs and combination treatments have been evaluated and found effective in treating multiple myeloma. However, most, if not all, of these patients inevitably relapse. Currently, there remains a need in the immunotherapy field for alternative or improved compositions and methods for more efficiently treating autoimmune disease and cancer. SUMMARY [04] One aspect of the disclosure is a combination therapy comprising an anti-B-cell maturation antigen (BCMA) antigen binding protein, such as belantamab mafodotin, nirogacestat, and at least one additional active agent, such as an immunomodulatory imide drug (IMiD), an anti-CD38 antibody, a steroid, or a proteasome inhibitor. [05] Another aspect of the disclosure is a method of treating a B-cell disorders, including cancers, comprising administering therapeutically effective doses of components of the combination therapy. [06] Another aspect of the disclosure is a method of reducing ocular toxicity resulting from treatment for a B-cell disorder, including cancer, comprising administering therapeutically effective doses of components of the combination therapy. [07] Another aspect of the disclosure are kits. In some embodiments, a kit disclosed herein is for use in treatment of cancer. In some embodiments, a kit disclosed herein can comprise a combination disclosed herein and instructions for use in the treatment of cancer. [08] Yet another aspect of the disclosure are pre-filled syringes or autoinjector devices. In some embodiments, a pre-filled syringe or autoinjector device disclosed herein can comprise a combination disclosed herein. DETAILED DESCRIPTION [09] This disclosure provides combination therapies and their use for treating B-cell disorders, including cancers. [10] “Combination therapy” means a therapy comprising two or more active agents. The two or more active agents can be administered in separate dosage forms (e.g., a first agent could be lyophilized powder, a second agent could be aqueous solution, and a third or more agents could be a tablet, capsule, or other oral dosage form). The two or more active agents can be administered at the same time or at separate times and can each be administered by the same route or by different routes (e.g., a first agent could be administered intravenously, a second agent could be administered subcutaneously, and a third or more agents could be administered orally). [11] “Newly diagnosed multiple myeloma” as used herein means multiple myeloma not previously treated with a standard of care (SoC) treatment for multiple myeloma. [12] “Q3W” refers to administration once every three weeks. “Q4W” refers to administration once every four weeks. “Q6W” refers to administration once every six weeks. “Q8W” refers to administration once every eight weeks. “Q10W” refers to administration once every ten weeks. “Q12W” refers to administration once every twelve weeks. [13] “BID” refers to administration twice a day. “QD” refers to administration once a day. [14] The disclosed combination therapies comprise an anti-BCMA antigen binding protein, such as belantamab mafodotin, and a gamma-secretase inhibitor, such as nirogacestat (PF-0308014), crenigacestat (LY3039478), CB-103, tarenflurbil, semagacestat (LY450139), RG-4733, EVP- 0962, avagacestat, MK-0752, BMS-906024, derivatives, or polymorphs thereof. [15] In some embodiments, administering a therapeutically effective dose of the combination reduces ocular toxicity as compared to administering a therapeutically effective amount of the anti- BCMA antigen binding protein. “Ocular toxicity” refers to any unintended exposure of a therapeutic agent to ocular tissue. Ocular toxicity can include changes in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and/or changes in visual acuity. Anti-BCMA Antigen Binding Proteins [16] The term “anti-BCMA antigen binding protein” as used herein refers to antibodies and other protein constructs, such as domains, that are capable of binding to BCMA. The terms “BCMA binding protein” and “BCMA antigen binding protein” are used interchangeably herein. This does not include the natural cognate ligand or receptor. [17] The anti-BCMA antigen binding proteins described herein may bind to human BCMA including, for example, human BCMA containing the amino acid sequence of GenBank Accession Number Q02223.2, or genes encoding human BCMA having at least 90 percent homology or at least 90% identity thereto. [18] Examples of anti-BCMA antigen binding proteins and methods of making the same are disclosed in International Publication No. WO2012/163805. Additional exemplary anti-BCMA antigen binding proteins include those described in WO2016/014789, WO2016/090320, WO2016/090327, WO2016/020332, WO2016/079177, WO2014/122143, WO2014/122144, WO2017/021450, WO2016/014565, WO2014/068079, WO2015/166649, WO2015/158671, WO2015/052536, WO2014/140248, WO2013/072415, WO2013/072406, WO2014/089335, US2017/165373, WO2013/154760, WO2018/201051, and WO2017/051068. [19] In some embodiments, the anti-BCMA antigen binding protein is an anti-BCMA antibody. The term “antibody” is used herein in the broadest sense to refer to molecules with an immunoglobulin-like domain (for example IgG, IgM, IgA, IgD or IgE) and includes monoclonal, recombinant, polyclonal, chimeric, human, humanized, multispecific antibodies, including bispecific antibodies, and heteroconjugate antibodies; a single variable domain (e.g., a domain antibody (DAB)), antigen binding antibody fragments, Fab, F(ab′) ₂ , Fv, disulfide linked Fv, single chain Fv, disulfide-linked scFv, diabodies, Tandem diabodies (TandAbs), etc. and modified versions of any of the foregoing (for a summary of alternative “antibody” formats see Holliger and Hudson, Nature Biotechnology, 2005, Vol 23, No.9, 1126-1136). [20] Full, whole, or intact antibody, used interchangeably herein, refers to a heterotetrameric glycoprotein with an approximate molecular weight of 150,000 Daltons. An intact antibody is composed of two identical heavy chains (HCs) and two identical light chains (LCs) linked by covalent disulfide bonds. This H2L2 structure folds to form three functional domains comprising two antigen-binding fragments, known as ‘Fab’ fragments, and a ‘Fc’ crystallizable fragment. The Fab fragment is composed of the variable domain at the amino-terminus, variable heavy (VH) or variable light (VL), and the constant domain at the carboxyl terminus, CH1 (heavy) and CL (light). The Fc fragment is composed of two domains formed by dimerization of paired CH2 and CH3 regions. The Fc may elicit effector functions by binding to receptors on immune cells or by binding C1q, the first component of the classical complement pathway. The five classes of antibodies IgM, IgA, IgG, IgE and IgD are defined by distinct heavy chain amino acid sequences, which are called µ, α, γ, ε and δ respectively, each heavy chain can pair with either a Κ or λ light chain. The majority of antibodies in the serum belong to the IgG class, there are four isotypes of human IgG (IgG1, IgG2, IgG3 and IgG4), the sequences of which differ mainly in their hinge region. [21] Fully human antibodies can be obtained using a variety of methods, for example using yeast- based libraries or transgenic animals (e.g., mice) that are capable of producing repertoires of human antibodies. Yeast presenting human antibodies on their surface that bind to an antigen of interest can be selected using FACS (Fluorescence-Activated Cell Sorting) based methods or by capture on beads using labelled antigens. Transgenic animals that have been modified to express human immunoglobulin genes can be immunized with an antigen of interest and antigen-specific human antibodies isolated using B-cell sorting techniques. Human antibodies produced using these techniques can then be characterized for desired properties such as affinity, developability and selectivity. [22] Alternative antibody formats include alternative scaffolds in which the one or more CDRs of the antigen binding protein can be arranged onto a suitable non-immunoglobulin protein scaffold or skeleton, such as an affibody, a SpA scaffold, an LDL receptor class A domain, an avimer (see, e.g., U.S. Patent Application Publication Nos. 2005/0053973, 2005/0089932, 2005/0164301) or an EGF domain. [23] “CDRs” are defined as the complementarity determining region amino acid sequences of an antigen binding protein. These are the hypervariable regions of immunoglobulin heavy and light chains. There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, "CDRs" as used herein refers to all three heavy chain CDRs, all three light chain CDRs, all heavy and light chain CDRs, or at least two CDRs. [24] Throughout this specification, amino acid residues in variable domain sequences and variable domain regions within full-length antigen binding sequences, e.g., within an antibody heavy chain sequence or antibody light chain sequence, are numbered according to the Kabat numbering convention. Similarly, the terms “CDR,” “CDRL1,” “CDRL2,” “CDRL3,” “CDRH1,” “CDRH2,” “CDRH3” follow the Kabat numbering convention. For further information, see Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987). [25] It will be apparent to those skilled in the art that there are alternative numbering conventions for amino acid residues in variable domain sequences and full-length antibody sequences. There are also alternative numbering conventions for CDR sequences, for example those set out in Chothia et al. (1989) Nature 342: 877-883. The structure and protein folding of the antigen binding protein may mean that other residues are considered part of the CDR sequence and would be understood to be so by a skilled person. [26] Other numbering conventions for CDR sequences available to a skilled person include “AbM” (University of Bath) and “contact” (University College London) methods. [27] In some embodiments, an anti-BCMA binding protein comprises any one or a combination of the following CDRs shown in the table below. Table 1. Examples CDR sequences for an anti-BCMA antigen binding protein. [28] CDRs may be modified by at least one amino acid substitution, deletion or addition, wherein the variant antigen binding protein substantially retains the biological characteristics of the unmodified protein, such as binding to the antigen. [29] In some embodiments, the anti-BCMA antigen binding protein comprises CDRH1 according to SEQ ID NO:1, CDRH2 according to SEQ ID NO:2, CDRH3 according to SEQ ID NO:3, CDRL1 according to SEQ ID NO:4, CDRL2 according to SEQ ID NO:5, and CDRL3 according to SEQ ID NO:6. [30] In some embodiments, the anti-BCMA antigen binding protein comprises CDR sequences which have at least 90% or 95% or 99% sequence identity to CDRH1 according to SEQ ID NO:1, CDRH2 according to SEQ ID NO:2, CDRH3 according to SEQ ID NO:3, CDRL1 according to SEQ ID NO:4, CDRL2 according to SEQ ID NO:5, and/or CDRL3 according to SEQ ID NO:6. “Percent identity” or “% identity” between a query amino acid sequence and a subject amino acid sequence is the “Identities” value, expressed as a percentage, that is calculated using a suitable algorithm (e.g., BLASTP, FASTA, Needleman-Wunsch, Smith-Waterman, LALIGN, or GenePAST/KERR) or software (e.g., DNASTAR ^® LASERGENE ^® , GENOMEQUEST ^® , EMBOSS needle or EMBOSS infoalign), over the entire length of the query sequence after a pair- wise global sequence alignment has been performed using a suitable algorithm (e.g., Needleman- Wunsch or GenePAST/KERR) or software (e.g., DNASTAR ^® LASERGENE ^® or GenePAST/KERR). Importantly, a query amino acid sequence may be described by an amino acid sequence disclosed herein, in particular in one or more of the claims. [31] The query sequence may be 100% identical to the subject sequence, or it may include up to a certain integer number of amino acid or nucleotide alterations as compared to the subject sequence such that the % identity is less than 100%. For example, the query sequence is at least 50, 60, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99% identical to the subject sequence. In the case of nucleic acid sequences, such alterations include at least one nucleotide residue deletion, substitution or insertion, wherein said alterations may occur at the 5′- or 3′-terminal positions of the query sequence or anywhere between those terminal positions, interspersed either individually among the nucleotide residues in the query sequence or in one or more contiguous groups within the query sequence. In the case of amino acid sequences, such alterations include at least one amino acid residue deletion, substitution (including conservative and non-conservative substitutions), or insertion, wherein said alterations may occur at the amino- or carboxy-terminal positions of the query sequence or anywhere between those terminal positions, interspersed either individually among the amino acid residues in the query sequence or in one or more contiguous groups within the query sequence. [32] For antibody sequences, the % identity may be determined across the entire length of the query sequence, including the CDRs. Alternatively, the % identity may exclude one or more or all of the CDRs, for example all of the CDRs are 100% identical to the subject sequence and the % identity variation is in the remaining portion of the query sequence, e.g., the framework sequence, so that the CDR sequences are fixed and intact. [33] In some embodiments, the anti-BCMA antigen binding protein comprises a heavy chain variable region (VH) according to SEQ ID NO:7 and a light chain variable region (VL) according to SEQ ID NO:8. SEQ ID NO:7 [34] In some embodiments, the anti-BCMA antigen binding protein comprises a heavy chain (H) according to SEQ ID NO:9 and a light chain (L) according to SEQ ID NO:10. SEQ ID NO:9 [35] In some embodiments, the anti-BCMA antigen binding protein is a T-cell redirecting antibody with dual inhibition of BCMA and CD3 receptors, such as teclistamab (Pillarisetti et al., Blood Advances 4, 4538-49, 2020) and blinatumomab, AMG 424, GBR 1342, BFR4350A, AMG 420, AMG 701, elranatamab (PF-06863135), REGN5458, TNB-383B (Alhallak et al., Cancers 13, 2853, 2021). In some embodiments, the anti-BCMA antigen binding protein is an afucosylated BCMA-directed antibody, such as SEA-BCMA (Van Epps et al., Cancer Res 2018;78(13 Suppl):Abstract nr 3833). CAR T Cell Therapeutics [36] In some embodiments, the anti-BCMA antigen binding protein is a CAR-T cell therapeutic, such as bb2121, ALLO-715, or PBCAR269A. See Raje et al., N. Engl. J. Med. 380, 1726-37, 2019); Abramson, Int. J. Mol. Sci.21, 5192, 2020. The term “chimeric antigen receptor” (“CAR”) as used herein, refers to an engineered receptor that consists of an extracellular antigen binding domain (usually derived from a monoclonal antibody, or fragment thereof, e.g., a VH domain and a VL domain in the form of a scFv), optionally a spacer region, a transmembrane region, and one or more intracellular effector domains. CARs have also been referred to as chimeric T cell receptors or chimeric immunoreceptors (CIRs). CARs are genetically introduced into hematopoietic cells, such as T cells, to redirect T cell specificity for a desired cell-surface antigen, resulting in a CAR-T therapeutic. [37] The term “spacer region” as used herein, refers to an oligo- or polypeptide that functions to link the transmembrane domain to the target binding domain. This region may also be referred to as a “hinge region” or “stalk region.” The size of the spacer can be varied depending on the position of the target epitope in order to maintain a set distance (e.g., 14 nm) upon CAR:target binding. The term “transmembrane domain” as used herein, refers to the part of the CAR molecule that traverses the cell membrane. [38] The term “intracellular effector domain” (also referred to as the “signaling domain”) as used herein refers to the domain in the CAR that is responsible for intracellular signaling following the binding of the antigen binding domain to the target. The intracellular effector domain is responsible for the activation of at least one of the normal effector functions of the immune cell in which the CAR is expressed. For example, the effector function of a T cell can be a cytolytic activity or helper activity including the secretion of cytokines. [39] It will be appreciated by a person skilled in the art that VH and/or VL domains disclosed herein may be incorporated, e.g., in the form of a scFv, into CAR-T therapeutics. Immunoconjugates [40] In some embodiments, the anti-BCMA antigen binding protein is used in an immunoconjugate. An “immunoconjugate” (interchangeably referred to as an “antibody-drug conjugate,” “ADC,” or “antigen binding protein-drug conjugate”) comprises an anti-BCMA antigen binding protein conjugated to one or more drugs, such as a cytotoxic agent, such as a chemotherapeutic agent, an immunotherapeutic agent, a growth inhibitory agent, a toxin (e.g., a protein toxin, such as an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), an antiviral agent, a radioactive isotope (i.e., a radioconjugate), an antibiotic, or a small interfering RNA (siRNA). [41] In some embodiments, an immunoconjugate has the following general structure: ABP-((Linker) _n -Ctx) _m wherein: ABP is an anti-BCMA antigen binding protein; Linker is either absent or is any a cleavable or non-cleavable linker; Ctx is any cytotoxic agent described herein; n is 0, 1, 2, or 3; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. [42] Examples of linkers include Val-Cit linkers (e.g., Val-Cit-PAB-OH, Fmoc-Val-Cit-PAB- OH, Fmoc-Val-Cit-PAB-PNP, Boc-Val-Cit, Boc-Val-Cit-PAB, Boc-Val-Cit-PAB-PNP, MC (C5)-Val-Cit, MC-Val-Cit-PAB-OH, MC-Val-Cit-PAB-PNP, SPDP-Val-Cit-PAB-OH, SPDP- Val-Cit-PAB-PNP, Mal-PEG2-Val-Cit-PAB-OH, Mal-PEG4-Val-Cit-PAB-OH, Mal-PEG1-Val- Cit-PAB-PNP, Mal-PEG4-Val-Cit-PAB-PNP, Mal-amido-PEG2-Val-Cit-PAB-OH, Mal-amido- PEG2-Val-Cit-PAB-PNP, Azido-PEG1-Val-Cit-PAB-OH, Azido-PEG3-Val-Cit-PAB-OH, Azido-PEG4-Val-Cit-PAB-OH, Azido-PEG3-Val-Cit-PAB-PNP, BCN-PEG3-Val-Cit, BCN- PEG3-VC-PFP Ester, DBCO-PEG4-Val-Cit-PAB-PNP, TCO-PEG4-Val-Cit-PAB-PNP); Val- Gly linkers (e.g., Boc-Val-Gly-OH, Mal-amido-PEG8-Val-Gly, Mal-amido-PEG8-val-gly-PAB- OH, , Boc-Gly-Gly, Fmoc-Gly-Gly-OH, Boc-Gly-Gly-N-[4-(hydroxymethyl)phenyl], Boc-Gly- Gly-Gly-OH, (S)-Benzyl 2-amino-N-[(carboxymethoxy)acetyl]-6-((tert- butoxycarbonyl)amino)hexanoate, Boc-Gly-Gly-Phe-Gly-OH, Fmoc-Gly-Gly-Gly-OH, Gly-Gly- Gly-PEG4-methyltetrazine, Gly-Gly-Gly-PEG3-TCO, Gly-Gly-Gly-PEG4-DBCO, TCO-PEG4- Fmoc-Gly-Gly-Gly, Biotin-PEG11-Gly-Gly-Gly-amine, Biotin-PEG12-Gly-Gly-Gly); Ala-Ala- Asn linkers (e.g., Fmoc-Ala-Pro-OH, Fmoc-Ala-Ser(Psi(Me,Me)pro)-OH, Fmoc-PEG4-Ala-Ala- Asn-PAB, Azido-PEG5-Ala-Ala-Asn-PAB, Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB, Azido-PEG4- Ala-Ala-Asn(Trt)-PAB, Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB-PNP); Sulfone-PEG-Acid linkers (e.g., Bis-sulfone-PEG4-Acid, Bis-Sulfone-PEG8-acid, Bis-sulfone-PEG12-Acid, Active-Mono- Sulfone-PEG8-acid); Sulfone-PEG-NHS ester linkers (e.g., Bis-sulfone NHS Ester, Bis-sulfone- PEG4-NHS Ester, Bis-sulfone-PEG8-NHS Ester, Bis-sulfone-PEG12-NHS Ester); PEG Linkers (e.g., Alkyne PEG, Amino PEG, Aminooxy PEG, APN PEG, BCN-PEG, Benzyl-PEG, Biotin PEG, Bis-PEG-acid, Bis-PEG-NHS, Boc-PEG, Branched PEG, Bromo PEG, Cleavable Linkers, DBCO PEG, Diketone Linkers, DNP-PEG, DOTA PEG, Fluorescent reagent, Fmoc PEG, Hydroxy PEG, Iodo PEG, Lipid PEG, m-PEG, Maleimide Linkers, MeNH-PEG, Non-PEG linker, PEG Acid, PEG Aldehyde, PEG Azide, PEG Hydrazide, PEG NHS ester, PEG PFP ester, PEG Phosphonate, PEG Silane, PEG Sulfonic acid, PEG Tosylate, PEG-X-PEG, Peptide Linkers, Poly PEG, Propargyl PEG, PROTAC PEG, SPDP PEG, Sugar PEG, TCO-PEG, Tetrazine-PEG, Thiol PEG); disulfide linkers (e.g., Aminoethyl-SS-ethylalcohol, Aminoethyl-SS-propionic acid, Amino-SS-PEG12-acid, Aminoethyl-SS-ethylamine, t-Boc-Cystamine, Azidoethyl-SS-propionic acid, Azido-SS-PEG2-acid, Azidoethyl-SS-propionic NHS ester, 3-[[2-[(4- azidobenzoyl)amino]ethyl]dithio]propanoicacid, Azido-Phenyl-Amido-S-S-Sulfo-NHS, Azidoethyl-SS-ethylalcohol, Azidoethyl-SS-ethylamine, Azidoethyl-SS-ethylazide, Azido-PEG3- SS-PEG3-azide, Azidoethyl-PEG2-t-Butyl ester, Propargyl-PEG1-SS-alcohol, Propargyl-PEG1- SS-PEG1-acid, Propargyl-PEG1-SS-PEG1-PFP ester, Propargyl-PEG1-SS-PEG1-propargyl, Propargyl-PEG1-SS-PEG1-t-butyl ester, 4-Azide-TFP-Amide-SS-propionic acid, 4-Azide-TFP- Amide-SS-Sulfo-NHS, Acid-PEG2-SS-PEG2-acid, Acid-PEG3-SS-PEG3-acid, Acid-PEG4-S-S- PEG4-acid, Acid-PEG6-SS-PEG6-acid, Boc-NH-ethyl-SS-propionic acid, Boc-aminooxy-ethyl- SS-propanol, Fmoc-NH-ethyl-SS-propionic acid, Fmoc-NH-ethyl-SS-propionic NHS ester, Mal- NH-ethyl-SS-propionic acid, (S)-2-amino-4-(2-(pyridin-2-yl)disulfanyl)butanoic acid, N-(2,2,2- Trifluoroacetyl)-3-[(2-aminoethyl)dithio]propanoic acid, Trifluoroacetamidoethyl-SS-propionic NHS ester, Hydroxy-PEG3-SS-PEG3-alcohol, m-PEG6-SS-PEG6-methyl, THP-SS-alcohol, THP-SS-PEG1-t-butyl ester, THP-SS-PEG1-Tos, 2-hydroxyethyl disulfide mono-Tosylate, Bis- Tos-(2-hydroxyethyl disulfide), Biotin-SS-Amine HCl Salt, Azide-SS-biotin, DBCO-S-S-PEG3- biotin, Biotin-PEG4-S-S-acid, Biotin-bisamido-SS-NHS, NHS-SS-biotin, Sulfo-NHS-SS-biotin, Biotin-PEG4-S-S-NHS, Bis-(Norbornene-PEG23)-disulfides); photocleavable linkers (e.g., PC Biotin-PEG3-alkyne, PC-Biotin-PEG4-PEG4-alkyne, PC Biotin-PEG3-azide, PC-Biotin-PEG4- PEG3-azide, PC Biotin-PEG3-NHS carbonate ester, PC-Biotin-PEG4, PC-Biotin-PEG4-NHS carbonate, PC DBCO-PEG3-biotin, PC SPDP-NHS carbonate ester, PC Alkyne-PEG4-NHS carbonate ester, PC Mal-NHS carbonate ester, PC Azido-PEG3-NHS carbonate ester, PC Azido- PEG11-NHS carbonate ester, 4-Azide-TFP-Amide-PEG4-acid); and enzymatically cleavable linkers (e.g., Mal-PEG2-Val-Cit-PAB-OH, Mal-PEG4-Val-Cit-PAB-OH, Mal-PEG1-Val-Cit- PAB-PNP, Mal-PEG4-Val-Cit-PAB-PNP, Mal-amido-PEG2-Val-Cit-PAB-OH, Mal-amido- PEG2-Val-Cit-PAB-PNP, Azido-PEG1-Val-Cit-PAB-OH, Azido-PEG3-Val-Cit-PAB-OH, Azido-PEG4-Val-Cit-PAB-OH, Azido-PEG3-Val-Cit-PAB-PNP, BCN-PEG3-Val-Cit, BCN- PEG3-VC-PFP Ester, DBCO-PEG4-Val-Cit-PAB-PNP, TCO-PEG4-Val-Cit-PAB-PNP). [43] In some embodiments, the linker is 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine- phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N- Succinimidyl 4-(2- pyridylthio)pentanoate (SPP), N-succinimidyl 4-(N- maleimidomethyl)cyclohexane-1 carboxylate (SMCC), or N-succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB). [44] In some embodiments, the immunoconjugate comprises an anti-BCMA monoclonal antibody linked to a cytotoxin. Examples of cytotoxins include Monomethyl auristatin E (MMAE), D8-MMAE, MMAF hydrochloride, PF-06380101, D8-MMAF hydrochloride, Dolastatin 10, MMAF sodium, Auristatin E, MMAF-OMe, MMAF, PF-06380101 D8, Calicheamicin, SN-38, Camptothecin, Dxd, 7-MAD-MDCPT, Top1 inhibitor 1, Doxorubicin hydrochloride, Daunorubicin hydrochloride, Aldoxorubicin, PNU-159682, Daun02, Daunorubicin, PNU-159682 carboxylic acid, DMEA-PNU-159682, Duocarmycin DM, Duocarmycin DM free base, Duocarmycin TM, DC1SMe Duocarmycin A, Duocarmycin SA, DC1, (+)-CBI-CDP12, Duocarmycin Analog, Duocarmycin MB, SG3199, Py-MPB-amino-C3-PBD, Aniline-MPB- amino-C3-PBD, Dimethyl-SGD-1882, Paclitaxel, Methotrexate, α-Amanitin, Taltobulin, Taltobulin hydrochloride, Taltobulin trifluoroacetate, 10-Deacetyl7-xylosyl paclitaxel, C11, β- Amanitin, Tubulysin A, and Telomestatin. [45] In some embodiments, the immunoconjugate comprises an anti-BCMA monoclonal antibody linked to dovaline-valine-dolaisoleunine-dolaproine-phenylalanine (MMAF) or monomethyl auristatin E (MMAE). In other embodiments, the immunoconjugate comprises a monoclonal antibody linked to MMAF or MMAE by a maleimidocaproyl (MC) linker as depicted in the following structures: Embodiments Comprising Belantamab Mafodotin [46] In some embodiments, the immunoconjugate is belantamab mafodotin. Belantamab mafodotin comprises an anti-BCMA-antibody conjugated to a microtubule inhibitor (monomethyl auristatin F, MMAF) via a maleimidocaproyl linker and is described in the U.S. Prescribing Information for BLENREP ^® (belantamab mafodotin-blmf). As described in the current prescribing information, the recommended dose for BLENREP ^® is 2.5 mg/kg as an intravenous infusion over approximately 30 minutes once every 3 weeks. At the presently recommended dose, eye problems are common. Indeed, as explained in the current prescribing information, it is known that BLENREP ^® can cause changes to the surface of a patient’s eye that can lead to dry eyes, blurred vision, worsening vision, severe vision loss, and corneal ulcers. [47] In some embodiments, the disclosed combination therapies overcome these deficiencies by using a combination therapy that significantly lowers the previously recommended dose of BLENREP ^® and/or increases the interval between administrations of BLENREP ^® . The lower dose of BLENREP ^® and/or increased interval between administrations of BLENREP ^® may advantageously reduce some of the previously known side effects associated with the drug. In some embodiments, as described below, the combination therapy further includes at least one additional active agent. [48] In some embodiments, a combination therapy comprises (a) belantamab mafodotin and (b) nirogacestat. In some embodiments, the gamma-secretase inhibitor is nirogacestat. Nirogacestat, (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)a mino)-N-(1-(2-methyl-1- (neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentamide, has the chemical structure of: [49] In some embodiments, a combination therapy comprises (a) belantamab mafodotin at a dose of at least about 0.5 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.7 mg/kg, 1.92 mg/kg, or 4.6 mg/kg and, independently, (b) nirogacestat at a dose of at least about 50, 100, 150, 200, or 250 mg. [50] In some embodiments, a combination therapy comprises therapeutically effective doses of each of belantamab mafodotin, nirogacestat, and at least one additional active agent, such as an immunomodulatory imide drug (IMiD), an anti-CD38 antibody, or a proteasome inhibitor. In some embodiments, the combination therapy comprises at least about 50, 100, 150, 200, or 250 mg of nirogacestat and, independently, at least about 0.5 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg of belantamab mafodotin. [51] In some embodiments a combination therapy comprises therapeutically effective doses of each of belantamab mafodotin, at least one additional active agent, such as an immunomodulatory imide drug (IMiD), an anti-CD38 antibody, or a proteasome inhibitor, and Form A polymorph of nirogacestat dihydrobromide (a dihydrobromide salt of (S)-2-(((S)-6,8-difluoro-l,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(l-(2-methyl-l-(neopentyl amino)propan-2-yl)-lH- imidazol- 4-yl)pentanamide of Formula (I)) [52] Form A of nirogacestat dihydrobromide is characterized by an XRPD pattern having peaks at 8.8 ± 0.2, 9.8 ± 0.2, and 23.3 ± 0.2 degrees two theta. [53] In one aspect, crystalline Form A of nirogacestat dihydrobromide is anhydrous. In another aspect, the melting point of crystalline Form A of nirogacestat dihydrobromide is about 254 °C. [54] In another aspect, Form A of nirogacestat dihydrobromide is characterized by an XRPD pattern having peaks at 8.8 ± 0.2, 9.8 ± 0.2, and 23.3 ± 0.2 degrees two theta when measured by Cu Ka radiation. In another aspect, Form A of nirogacestat dihydrobromide is characterized by an XRPD pattern having peaks at 8.8 ± 0.2, 9.8 ± 0.2, 23.3 ± 0.2, 25.4 ± 0.2, 28.0 ± 0.2, and 29.3 ± 0.2 degrees two theta when measured by Cu Ka radiation. [55] In another aspect, Form A of nirogacestat dihydrobromide is characterized by an XRPD pattern having peaks at 8.8 ± 0.2, 9.8 ± 0.2, 20.0 ± 0.2, 23.3 ± 0.2, 25.4 ± 0.2, 28.0 ± 0.2, 29.3 ± 0.2, and 32.5 ± 0.2 degrees two theta when measured by Cu Ka radiation. [56] In some embodiments, the additional active agent is an immunomodulatory imide drug (IMiD). Examples of IMiDs include, but are not limited to, thalidomide (e.g., THALOMID ^® , lenalidomide (e.g., REVLIMID ^® ), and pomalidomide (e.g., POMALYST ^® ). [57] In some embodiments, the additional active agent is an anti-CD38 antibody. Examples of anti-CD38 antibodies include, but are not limited to, isatuximab and isatuximab-irfc (e.g., SARCLISA ^® ), and daratumumab (e.g, DARZALEX ^® , DARZALEX FASPRO ^® ). [58] In some embodiments, the additional active agent is a proteasome inhibitor. Examples of proteasome inhibitors include, but are not limited to, bortezomib (e.g., VELCADE ^® ), ixazomib (e.g., NINLARO ^® ), carfilzomib (e.g., KYPROLIS ^® ), oprozomib, and delanzomib. [59] In any of the embodiments described herein, the combination therapy further comprises a therapeutically effective dose of a corticosteroid, such as dexamethasone (e.g., DECADRON ^® , DEXASONE ^® , DIODEX ^® , HEXADROL ^® , MAXIDEX ^® ), prednisone (e.g., DELTASONE ^® ), or methylprednisolone (e.g., MEDROL ^® ). [60] In any of the embodiments described herein, another anti-BCMA antigen binding protein can be used in place of belantamab mafodotin. Methods of Treatment and Uses [61] The disclosed combination therapies can be used to treat B-cell mediated disorders, including cancers, in a patient need of such treatment. “Treating” as used herein refers to alleviating one or more symptoms or effects associated with a disorder and/or slowing the progression of the disorder. [62] “B-cell disorders” include immunodeficiencies and disorders characterized by excessive or uncontrolled proliferation, such as acute glomerulonephritis, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), epidermolysis bullosa acquisita, extramedullary), follicular lymphoma (FL), Goodpasture’s syndrome, heavy chain disease, Hodgkin’s lymphoma (HL), idiopathic thrombocytopenic purpura (ITP), light chain deposition disease, lymphoplasmacytic lymphoma (LPL), monoclonal gammopathy of undetermined significance (MGU.S.), multiple myeloma (MM), non-Hodgkin’s lymphoma B-cell leukemia (NHL), non-secretory multiple myeloma, pemphigus and pemphigoid disorders, plasma cell leukemia, POEMS syndrome / osteosclerotic myeloma, primary amyloidosis (AL), smoldering multiple myeloma, solitary plasmacytoma (bone, systemic lupus erythematosus SLE), Type I and II cryoglobulinemia, and Waldenström’s macroglobulinemia. [63] In some embodiments, the disorder is a leukemia (e.g., chronic myelocytic leukemia, acute myelocytic leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia). In some embodiments, the disorder is a lymphoma, such as non-Hodgkin’s lymphoma or Hodgkin’s lymphoma. In some embodiments, the disorder is a plasma cell malignancy (e.g., multiple myeloma, plasma cell myeloma, plasmablastic lymphoma, anaplastic lymphoma kinase positive large B-cell lymphoma). [64] In some embodiments, the disclosed combination therapies reduce ocular toxicity (e.g., changes in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, changes in visual acuity) as compared to administering a therapeutically effective amount of the anti- BCMA antigen binding protein (e.g., belantamab mafodotin) without a therapeutically effective amount of the gamma-secretase inhibitor (e.g., nirogacestat). Detection of ocular toxicity may be determined by ophthalmic examination by an ophthalmologist or optometrist, before, during, and/or after treatment. [65] An ophthalmic examination may include one or more of the following: 1. Best corrected visual acuity, 2. Documentation of manifest refraction and the method used to obtain best corrected visual acuity, 3. Current glasses prescription (if applicable), 4. Intraocular pressure measurement, 5. Anterior segment (slit lamp) examination including fluorescein staining of the cornea and lens examination, 6. Dilated funduscopic examination, and/or 7. An ocular surface disease index (OSDI) which is visual function questionnaire that assess the impact of potential ocular change in vision on function and health-related quality of life. [66] In some embodiments, reducing ocular toxicity refers to reducing the severity of a corneal adverse reaction or the grade of a treatment related corneal toxicity as determined according to the KVA scale.

Abbreviations: BCVA=best corrected visual acuity; KVA=keratopathy visual acuity; logMAR=logarithm of the minimum angle of resolution; SPK=superficial punctate keratitis. [67] An example of a route of administration and dosage schedule for belantamab mafodotin is disclosed in the U.S. Prescribing Information for BLENREP ^® . For example, in some embodiments BLENREP ^® is administered at a dose of 2.5 mg/kg as an intravenous infusion over approximately 30 minutes once every three weeks. [68] Combination therapies of anti-BCMA antigen binding proteins and gamma-secretase inhibitors, including dosages, duration of treatment, and time lapses between administration of the two agents, are disclosed in WO 2020/208572. In some embodiments, gamma-secretase inhibitor (e.g., nirogacestat) may be administered once or twice daily (e.g., QD or BID). [69] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 3.4 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 150 mg. [70] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 2.5 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 150 mg. [71] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1.9 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 150 mg. [72] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 0.95 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 150 mg. [73] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 0.50 mg/kg and the gamma-secretase inhibitor is administered at a dose of about 150 mg. [74] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 150 mg. [75] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1.4 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 150 mg. [76] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 3.4 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 100 mg. [77] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 2.5 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 100 mg. [78] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1.9 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 100 mg. [79] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 0.95 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 100 mg. [80] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 0.5 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 100 mg [81] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 100 mg. [82] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1.4 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 100 mg. [83] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 3.4 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 50 mg. [84] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 2.5 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 50 mg. [85] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1.9 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 50 mg. [86] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 50 mg. [87] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 1.4 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 50 mg. [88] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 0.95 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 50 mg. [89] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose of about 0.5 mg/kg, and the gamma-secretase inhibitor is administered at a dose of about 50 mg. [90] In some embodiments, the anti-BCMA antigen binding protein is administered at a dose disclosed herein at Q3/4W, Q3/4/6/8W or Q3/4/6/8W. In some embodiments, the anti-BCMA antigen binding protein is administered at three-weekly (Q3W) dose on Day 1 of every 21-day cycle for the first 8 cycles. From cycle 9 onwards, the anti-BCMA antigen binding protein is administered at four-weekly (Q4W) dose on Day 1 of every 28-day cycle. In some embodiments, the anti-BCMA antigen binding protein is administered at six-weekly (Q6W) dose on Day 1 of every other 21-day cycle for the first 8 cycles. From cycle 9 onwards, the anti-BCMA antigen binding protein is administered at eight-weekly (Q8W) dose on Day 1 of every third 21-day cycle. [91] Nirogacestat may be administered BID or QD orally in combination with belantamab mafodotin. In exemplary embodiments, the gamma-secretase inhibitor (e.g., nirogacestat) is administered at 100 mg twice daily (BID). In other exemplary embodiments, the gamma-secretase inhibitor is administered at 100 mg once daily (QD). In some embodiments, the gamma-secretase inhibitor is given every day. In some embodiments, the gamma-secretase inhibitor may be given on a “7-day on/14-day off” schedule, wherein the gamma-secretase inhibitor is administered twice daily (BID) on days 1-7 of a 21-day cycle and is not administered on day 8 through day 14. In some embodiments, the gamma-secretase inhibitor (e.g., nirogacestat) is administered twice daily (BID) on days 1-28 of a 28-day cycle. In some embodiments, the gamma-secretase inhibitor (e.g., nirogacestat) is administered twice daily (BID) on days 1-21 of a 56-day cycle. In some embodiments, the gamma-secretase inhibitor (e.g., nirogacestat) is administered twice daily (BID) on days 1-21 of a 56-day cycle and the gamma-secretase inhibitor (e.g., nirogacestat) is not administered on days 29-56 of the 56-day cycle. In some embodiments, the gamma-secretase inhibitor (e.g., nirogacestat) is administered twice daily (BID) on days 1-21 of a 84-day cycle. In some embodiments, the gamma-secretase inhibitor (e.g., nirogacestat) is administered twice daily (BID) on days 1-21 of a 84-day cycle and the gamma-secretase inhibitor (e.g., nirogacestat) is not administered on days 29-84 of the 84-day cycle. [92] In some embodiments, the gamma-secretase inhibitor (e.g., nirogacestat) is administered on a negative day of a cycle. For instance, the gamma-secretase inhibitor (e.g., nirogacestat) is administered on day -1 or day -2 of a cycle, such as a 28-day cycle. Administration on a negative day of a cycle refers to administration on the stated number of days prior to day 1 of the cycle. Thus, administration on day -2 of a cycle occurs two days before day 1 of the cycle, and administration on day -1 of a cycle occurs the day before day 1 of the cycle. [93] In some embodiments, the gamma-secretase inhibitor may be administered concurrently or sequentially to the anti-BCMA antigen binding protein. In some embodiments, the gamma- secretase inhibitor is administered before the anti-BCMA antigen binding protein. For example, in some embodiments, the gamma-secretase inhibitor is administered at least 1 hour before the anti- BCMA antigen binding protein. [94] In some embodiments, the combination of (belantamab or belantamab mafodotin) and nirogacestat may be administered in 2-week, 4-week, 6-week, and 8-week cycles. In exemplary embodiments the combination of (belantamab or belantamab mafodotin) and nirogacestat may be administered in a 4-week cycle, i.e., 28 days. In other exemplary embodiments the combination of (belantamab or belantamab mafodotin) and nirogacestat may be administered in a 8-week cycle, i.e., 56 days. In exemplary embodiments, nirogacestat may be taken (e.g., QD or BID) following the same dosing schedule as (belantamab or belantamab mafodotin). For example, nirogacestat may be administered (e.g., QD or BID) in 4-week intervals separated by, e.g., 4 weeks, 8 weeks, or 12 weeks. [95] In some embodiments, nirogacestat may be taken (e.g., QD or BID) for 2 days prior to the first administration of (belantamab or belantamab mafodotin), e.g., 2 days before Cycle 1 Day 1. In some embodiments, nirogacestat may be taken (e.g., QD or BID) on the same day as the first administration of (belantamab or belantamab mafodotin), e.g., on Day 1 of Cycle 1. [96] In some embodiments, nirogacestat may be taken (e.g., QD or BID) for 2 days prior to the first administration of (belantamab or belantamab mafodotin) through day 28 (e.g., day -2 to day 28 of a cycle) and nirogacestat is then not administered in a subsequent cycle, e.g., nirogacestat would not be taken during cycle 2 (i.e., from Days 29-56) and/or during cycle 3 (i.e., from Days 57-84). In some embodiments, nirogacestat may be administered (e.g., QD or BID) with the first administration of (belantamab or belantamab mafodotin) through day 28 and nirogacestat is then not administered in a subsequent cycle, e.g., nirogacestat would not be taken during cycle 2 (i.e., from Days 29-56) and/or during cycle 3 (i.e., from Days 57-84). In some embodiments, nirogacestat may be administered (e.g., QD or BID) from Day 1 through Day 28 and not from Days 29-84. [97] In some embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may reduce the risk and/or severity of toxicity (e.g., ocular toxicity). In other embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may provide increased efficacy. In other embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may enhance treatment (e.g., reduce toxicity and/or improve efficacy) compared to (belantamab or belantamab mafodotin) monotherapy. For example, the combination of (belantamab or belantamab mafodotin) and nirogacestat may reduce the risk and the severity of the ocular toxicity compared to (belantamab or belantamab mafodotin) monotherapy. In some examples, the reduction in toxicity may allow for higher doses or more frequent dosing of (belantamab or belantamab mafodotin). In other examples, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may allow for lower doses and/or less frequent dosing of (belantamab or belantamab mafodotin). [98] In some embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may allow a 50% dose reduction compared to (belantamab or belantamab mafodotin) monotherapy. In some embodiments, the combination may enhance treatment using a dose of (belantamab or belantamab mafodotin) that is reduced more than 50% compared to (belantamab or belantamab mafodotin) monotherapy. In embodiments, the combination may enhance treatment using a dose of (belantamab or belantamab mafodotin) that is reduced 60% compared to (belantamab or belantamab mafodotin) monotherapy. For example, the dose of (belantamab or belantamab mafodotin) used in combination with nirogacestat may be reduced to less than 2.5 mg/kg. In other examples, the dose of (belantamab or belantamab mafodotin) used in combination with nirogacestat may be reduced to 1.0 mg/kg. In other examples, the dose of (belantamab or belantamab mafodotin) used in combination with nirogacestat may be reduced to 1.4 mg/kg. [99] In some embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may reduce the risk and/or severity of ocular toxicity (e.g., keratopathy). For example, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may reduce keratopathy to less than, e.g., 40%, 30%, 25%, 20%, 15% or 10%. In specific examples, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may reduce keratopathy to an incidence of less than 10%. [100] In some embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may provide increased efficacy. For example, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may provide an increased response and/or a prolongation of response. In exemplary embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may provide an Objective Response Rate of more than, e.g., 40%, 45% or 50%. In specific embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may provide an Objective Response Rate of more than 50%. In some embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may provide improvement in progression- free survival. In specific embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may provide an Objective Response Rate of more than 50% and improvement in progression-free survival. [101] In some embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may increase response rate in participants compared to (belantamab or belantamab mafodotin) monotherapy without a marked comparative worsening of the overall combination safety profile. In other embodiments, the combination of (belantamab or belantamab mafodotin) and a GSI (e.g., nirogacestat) may allow a lower dose of (belantamab or belantamab mafodotin) mafodotin to improve the overall safety profile of a treatment, e.g., by reducing the rate of ≥Grade 2 corneal toxicity. [102] Examples of routes of administration and dosage schedules for IMiDs are disclosed, for example, in the U.S. Prescribing Information for THALOMID ^® (thalidomide), REVLIMID ^® (lenalidomide), and POMALYST ^® (pomalidomide). For example, for treatment of multiple myeloma, THALOMID ^® is administered orally at a dose of 200 mg once daily together with 40 mg/day of dexamethasone on days 1-4, 9-12, and 17-20 every 28 days. [103] For multiple myeloma combination therapy with dexamethasone (20 mg or 40 mg once per day on days 1, 8, 15, and 22 of each 28-day cycle), REVLIMID ^® is administered at 25 mg once daily orally on days 1-21 of repeated 28-day cycles; for multiple myeloma maintenance therapy following autologous hematopoietic stem cell transplantation, REVLIMID ^® is administered at 10 mg once daily continuously on days 1-28 of repeated 28-day cycles; for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without cytogenetic abnormalities, REVLIMID ^® is administered at 10 mg once daily; for mantle cell lymphoma, REVLIMID ^® is administered at 25 mg once daily orally on days 1-21 of repeated 28-day cycles; and for previously treated follicular lymphoma or previously treated marginal zone lymphoma, REVLIMID ^® is administered at 20 mg once daily orally on days 1-21 of repeated 28-day cycles for up to 12 cycles in combination with a rituximab product. [104] For multiple myeloma, POMALYST ^® is administered orally at 4 mg on days 1-21 of repeated 28-day cycles until disease progression, in combination with dexamethasone (20 mg or 40 mg once per day on days 1, 8, 15, and 22 of each 28-day cycle). [105] Examples of routes of administration and dosage schedules for anti-CD38 antibodies are disclosed, for example, in the U.S. Prescribing Information for SARCLISA ^® (isatuximab and isatuximab-irfc); and DARZALEX ^® and DARZALEX FASPRO ^® (daratumumab). For example, for multiple myeloma, SARCLISA ^® is 10 mg/kg as an intravenous infusion every week for four weeks, in combination with pomalidomide (4 mg orally once daily from day 1 to day 21 of each 28-day cycle) and dexamethasone (orally or intravenously, 20 or 40 mg on days 1, 8, 15, and 22 of each 28-day cycle), followed by every two weeks until disease progression or unacceptable toxicity; and for treating relapsed or refractory multiple myeloma, SARCLISA ^® is administered in combination with carfilzomib (administered intravenously at 20 mg/m ² on days 1 and 2, 56 mg/m ² on days 8, 9, 15, and 16 of cycle 1 and each subsequent cycle) and dexamethasone (20 mg, administered intravenously on days of SARCLISA ^® and/or carfilzomib infusions, otherwise orally, on days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28 day cycle).

[106] For treatment of multiple myeloma, DARZALEX ^® is administered at 16 mg/kg of actual body weight, as an intravenous infusion, according to the following schedule: [107] In some embodiments, DARZALEX ^® is administered in combination with other agents, e.g., lenalidomide and dexamethasone; bortezomib, melphalan, and prednisone; bortezomib and dexamethasone; carfilzomib and dexamethasone; pomalidomide and dexamethasone, according to any of the following schedules:

[108] Examples of routes of administration and dosage schedules for proteasome inhibitors are disclosed, for example, in the U.S. Prescribing Information for VELCADE ^® (bortezomib), NINLARO ^® (ixazomib), and KYPROLIS ^® (carfilzomib). For example, to treat multiple myeloma or mantle cell lymphoma, VELCADE ^® is administered at 1.3 mg/m ² , either as a 3-5 second bolus intravenous injection or a subcutaneous injection. [109] To treat multiple myeloma, NINLARO ^® is administered at 4 mg, taken orally on days 1, 8, and 15 of a 28-day cycle, at least one hour before or at least two hours after food, in combination with lenalidomide (25 mg daily on days 1-21 of a 28-day treatment cycle) and dexamethasone (40 mg on days 1, 8, 15, and 22 of a 28-day treatment cycle). [110] To treat relapsed or refractory multiple myeloma, KYPROLIS ^® is administered according to either of the following schedules:

[111] In some embodiments, KYPROLIS ^® is administered in combination with lenalidomide and dexamethasone, according to the following schedule: [112] In some embodiments, KYPROLIS ^® is administered in combination with dexamethasone, according to any of the following schedules:

[113] In some embodiments, KYPROLIS ^® is administered in combination with dexamethasone daratumumab and dexamethasone, according to either of the following schedules:

[114] Non-limiting examples of combination therapies for multiple myeloma and other B-cell disorders are described below. In some embodiments where the disorder is multiple myeloma, the multiple myeloma is relapsed and/or refractory, and the patient has received at least one, at least two, at least three, or at least four prior therapies to treat the multiple myeloma, such as an anti- CD38 monoclonal antibody, a proteasome inhibitor, or an immunomodulatory agent (e.g., thalidomide, lenalidomide, pomalidomide). In some embodiments, the patient has received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. [115] In some embodiments, a combination therapy disclosed herein comprises an anti-BCMA antigen binding protein, a gamma secretase inhibitor and an IMiD. In some embodiments, a combination therapy disclosed herein comprises anti-BCMA antigen binding protein, a gamma secretase inhibitor, an IMiD and a steroid. In some embodiments, a combination therapy disclosed herein comprises anti-BCMA antigen binding protein, a gamma secretase inhibitor and an anti- CD38 therapy. In some embodiments, a combination therapy disclosed herein comprises anti- BCMA antigen binding protein, a gamma secretase inhibitor, an anti-CD38 therapy and a steroid. In some embodiments, a combination therapy disclosed herein comprises an anti-BCMA antigen binding protein, a gamma secretase inhibitor and a proteasome inhibitor. In some embodiments, a combination therapy disclosed herein comprises an anti-BCMA antigen binding protein, a gamma secretase inhibitor, a proteasome inhibitor and a steroid. In some embodiments, the anti-BCMA antigen binding protein is belantamab or belantamab mafodotin or a combination thereof. In some embodiments, the IMiD is lenalidomide or pomalidomide or a combination thereof. In some embodiments, the gamma secretase inhibitor is nirogacestat, a derivative or a polymorph thereof. In some embodiments, the steroid is dexamethasone. In some embodiments, the proteasome inhibitor is bortezomib. In some embodiments, the anti-CD38 therapy comprises isatuximab, isatuximab-irfc or daratumumab. Combination Therapies Comprising Lenalidomide for Treating Multiple Myeloma, Transfusion-Dependent Anemia, Mantle Cell Lymphoma, Follicular Lymphoma, and Marginal Zone Lymphoma [116] In some embodiments, a patient is treated with a combination therapy comprising therapeutically effective doses of belantamab mafodotin, nirogacestat, and lenalidomide. In some of these embodiments, the combination therapy also comprises a therapeutically effective dose of dexamethasone. See the U.S. Prescribing Information for REVLIMID ^® . [117] Some of these patients have multiple myeloma. Combination therapy for these patients includes 25 mg of lenalidomide once daily on days 1-21 of repeated 28-day cycles; and further comprises 20 or 40 mg of dexamethasone on days 1, 8, 15, and 22 of the repeated 28-day cycles. Combination therapy for patients who have multiple myeloma and have received autologous hematopoietic stem cell transplantation includes 10 mg of lenalidomide once daily on days 1-28 of repeated 28-day cycles. [118] Some of these patients have transfusion-dependent anemia due to low- or intermediate-1- risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities. Combination therapy for these patients includes 10 mg of lenalidomide once daily. [119] Some of these patients have mantle cell lymphoma (MCL) which has relapsed or progressed after two prior therapies, one of which included bortezomib. Combination therapy for these patients includes 25 mg of lenalidomide once daily on days 1-21 of repeated 28-day cycles. [120] Some of these patients have previously treated follicular lymphoma (FL) or previously treated marginal zone lymphoma (MZL). Combination therapy for these patients includes 20 mg of lenalidomide once daily on days 1-21 of repeated 28-day cycles for up to 12 cycles; and also includes treatment with a rituximab product dosed at 375 mg/m ² on days 1, 8, 15, and 22 of a first 28-day cycle (Cycle 1) and on day 1 of Cycles 2-5. [121] The dose of belantamab mafodotin administered as part of any of the combination therapies described above can be, for example, 0.5 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg, typically administered as an intravenous infusion every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In some embodiments, a dose of 1.0 mg/kg of belantamab mafodotin is administered every 3 or 4 weeks. In other embodiments, a dose of 1.4 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, every 8 weeks, or every 10 weeks. In other embodiments, a dose of 1.9 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In some embodiments, in a combination disclosed herein, 0.5 mg/kg, 09 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg anti-BCMA antigen binding protein is administered every 3 weeks, every 4 weeks, every 5 weeks, every 6 weeks, every 7 weeks, every 8 weeks, every 9 weeks, every 10 weeks, every 12 weeks, or every 15 weeks. [122] Independently, the dose of nirogacestat administered as part of any of the combination therapies described above can be, for example, at least about 50, 100, 150, 200, or 250 mg, administered once or twice daily. In some embodiments, 100 mg of nirogacestat is administered twice a day. [123] In one aspect, the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; wherein the IMiD is lenalidomide, and wherein the lenalidomide is administered orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [124] In some embodiments, the methods further comprise administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 of repeated 28-day cycles or (ii) 10 mg on each of days 1 to 21 of repeated 28-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40- 60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [125] In some embodiments, the methods further comprise administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56- day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [126] In some embodiments, the methods further comprise administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.0 mg/kg or 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [127] In one aspect, the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 0.5 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; wherein the IMiD is lenalidomide, and wherein the lenalidomide is administered orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28- day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 0.5 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 of repeated 28-day cycles or (ii) 10 mg on each of days 1 to 21 of repeated 28-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [128] In one aspect, the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; wherein the IMiD is lenalidomide, and wherein the lenalidomide is administered orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28- day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [129] In one aspect, the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; wherein the IMiD is lenalidomide, and wherein the lenalidomide is administered orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28- day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [130] In one aspect, the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; wherein the IMiD is lenalidomide, and wherein the lenalidomide is administered orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28- day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [131] In one aspect, the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; wherein the IMiD is lenalidomide, and wherein the lenalidomide is administered orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28- day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [132] In one aspect, the disclosure provides the use of: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid in the manufacture of a medicament for use in treating multiple myeloma in an individual. In one aspect, the disclosure provides: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid for use in treating multiple myeloma in an individual. [133] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; the IMiD is lenalidomide, and the lenalidomide is formulated for oral administration to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [134] In some embodiments, after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21 of repeated 28-day cycles or (ii) 10 mg on each of days 1 to 21 of repeated 28-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28- day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [135] In some embodiments, after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [136] In some embodiments, after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.0 mg/kg or 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40- 60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [137] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 0.5 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; the IMiD is lenalidomide, and the lenalidomide is formulated for oral administration to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 0.5 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21 of repeated 28-day cycles or (ii) 10 mg on each of days 1 to 21 of repeated 28-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [138] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; the IMiD is lenalidomide, and the lenalidomide is formulated for oral administration to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.0 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [139] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; the IMiD is lenalidomide, and the lenalidomide is formulated for oral administration to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.0 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [140] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; the IMiD is lenalidomide, and the lenalidomide is formulated for oral administration to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [141] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle; the IMiD is lenalidomide, and the lenalidomide is formulated for oral administration to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) lenalidomide is formulated for oral administration at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . Combination Therapies Comprising Pomalidomide for Treating Multiple Myeloma [142] In some embodiments, a patient with multiple myeloma is treated with a combination therapy comprising therapeutically effective doses of belantamab mafodotin, nirogacestat, and pomalidomide. In some of these embodiments, the combination therapy also comprises a therapeutically effective dose of dexamethasone. [143] In this example, combination therapy for multiple myeloma includes 4 mg of pomalidomide per day on days 1 through 21 of repeated 28-day cycles until disease progression. The combination therapy can include 20 mg or 40 mg of dexamethasone administered on days 1, 8, 15, and 22 of a 28-day cycle. In some embodiments, the patient has received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and has demonstrated disease progression on or within 60 days of completion of the last therapy. [144] The dose of belantamab mafodotin administered as part of any of the combination therapies described above can be, for example, 0.5 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg, typically administered as an intravenous infusion every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In some embodiments, a dose of 1.0 mg/kg of belantamab mafodotin is administered every 3 or 4 weeks. In other embodiments, a dose of 1.4 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In other embodiments, a dose of 1.9 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. [145] Independently, the dose of nirogacestat administered as part of any of the combination therapies described above can be, for example, at least about 50, 100, 150, 200, or 250 mg, administered once or twice daily. In some embodiments, 100 mg of nirogacestat is administered twice a day. [146] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [147] In some embodiments, the methods further comprise administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [148] In some embodiments, the methods further comprise administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [149] In some embodiments, the methods further comprise administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.0 mg/kg or 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [150] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 0.5 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 0.5 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [151] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [152] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [153] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [154] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [155] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [156] In one aspect the disclosure provides a method of treating multiple myeloma in an individual in need thereof, the method comprising administering to the individual: (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid, wherein the belantamab mafodotin is administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; wherein the nirogacestat is administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; wherein the IMiD is pomalidomide, and wherein the pomalidomide is administered orally to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and wherein the corticosteroid is dexamethasone, and wherein the dexamethasone is administered orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and the method further comprising administering to the individual after the initial 28-day cycle: (a) belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide orally at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [157] In one aspect the disclosure provides the use of (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid in the manufacture of a medicament for use in treating multiple myeloma in an individual. In one aspect the disclosure provides (a) a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid for use in treating multiple myeloma in an individual. [158] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [159] In some embodiments, after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [160] In some embodiments, after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [161] In some embodiments, after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.0 mg/kg or 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [162] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 0.5 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 0.5 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone is formulated for oral administration or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [163] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.0 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [164] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.0 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [165] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.0 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [166] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [167] In the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [168] In some embodiments, the belantamab mafodotin is formulated for intravenous administration to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle; the nirogacestat is formulated for oral administration to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28-day cycle; the IMiD is pomalidomide, and the pomalidomide is formulated for oral administration to the individual at a dose of 4 mg on each of days 1 to 21 of an initial 28-day cycle; and the corticosteroid is dexamethasone, and the dexamethasone is formulated for oral or intravenous administration to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² ; and wherein further after the initial 28-day cycle: (a) belantamab mafodotin is formulated for intravenous administration at a dose of 1.4 mg/kg on day 1 of repeated 28-day cycles; (b) nirogacestat is formulated for oral administration at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) pomalidomide is formulated for oral administration at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) dexamethasone is formulated for oral or intravenous administration at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . Combination Therapies Comprising Bortezomib for Multiple Myeloma and Mantle Cell Lymphoma [169] In some embodiments, a patient is treated with a combination therapy comprising therapeutically effective doses of belantamab mafodotin, nirogacestat, and bortezomib. In some of these embodiments, the combination therapy also comprises a therapeutically effective dose of dexamethasone or prednisone. See the U.S. Prescribing Information for VELCADE ^® . [170] Some of these patients have previously untreated multiple myeloma. Combination therapy for these patients typically comprises 9 6-week treatment cycles, in which 1.3 mg/m ² of bortezomib is administered either as a 3 to 5 second intravenous injection or subcutaneous injection. In some embodiments, the combination therapy also includes a therapeutically effective dose of melphalan and prednisone. In some embodiments, the combination therapy includes a therapeutically effective dose of dexamethasone. [171] Some of these patients have previously untreated mantle cell lymphoma. Combination therapy for these patients typically comprises 63-week treatment cycles, in which 1.3 mg/m ² of bortezomib is administered either as a 3 to 5 second intravenous injection or subcutaneous injection. In some embodiments, the combination therapy also includes a therapeutically effective dose of rituximab, cyclophosphamide, doxorubicin, and prednisone. In some embodiments, the combination therapy includes a therapeutically effective dose of dexamethasone. [172] The dose of belantamab mafodotin administered as part of any of the combination therapies described above can be, for example, 0.5 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg, typically administered as an intravenous infusion every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In some embodiments, a dose of 1.0 mg/kg of belantamab mafodotin is administered every 3 or 4 weeks. In other embodiments, a dose of 1.4 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In other embodiments, a dose of 1.9 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. [173] Independently, the dose of nirogacestat administered as part of any of the combination therapies described above can be, for example, at least about 50, 100, 150, 200, or 250 mg, administered once or twice daily. In some embodiments, 100 mg of nirogacestat is administered twice a day. Combination Therapies for Multiple Myeloma Comprising Isatuximab [174] In some embodiments, a patient with multiple myeloma is treated with a combination therapy comprising therapeutically effective doses of belantamab mafodotin, nirogacestat, and isatuximab. In some of these embodiments, the combination therapy also comprises a therapeutically effective dose of dexamethasone. In some of these embodiments, the combination therapy also comprises a therapeutically effective dose of dexamethasone and carfilzomib. See the U.S. Prescribing Information for SARCLISA ^® . [175] Isatuximab typically is administered by intravenous infusion of 10 mg/kg of isatuximab every week for 4 weeks, followed by every 2 weeks until disease progression or unacceptable toxicity. Some patients have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor. Some patients have relapsed or refractory multiple myeloma and have received 1 to 3 prior lines of therapy. Patients may be premedicated with dexamethasone, acetaminophen, H2 antagonists, and diphenhydramine. [176] The dose of belantamab mafodotin administered as part of any of the combination therapies described above can be, for example, 0.5 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg, typically administered as an intravenous infusion every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In some embodiments, a dose of 1.0 mg/kg of belantamab mafodotin is administered every 3 or 4 weeks. In other embodiments, a dose of 1.4 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In other embodiments, a dose of 1.9 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. [177] Independently, the dose of nirogacestat administered as part of any of the combination therapies described above can be, for example, at least about 50, 100, 150, 200, or 250 mg, administered once or twice daily. In some embodiments, 150 mg of nirogacestat is administered once a day. In other embodiments, 100 mg of nirogacestat is administered twice a day. In other embodiments, 100 mg of nirogacestat is administered once a day. Combination Therapies for Multiple Myeloma Comprising Daratumumab [178] In some embodiments, a patient with multiple myeloma is treated with a combination therapy comprising therapeutically effective doses of belantamab mafodotin, nirogacestat, and daratumumab. Daratumumab typically is administered at a dose of 16 mg/kg, with or without other active agents, according to schedules disclosed in the U.S. Prescribing Information for DARZALEX ^® . [179] In some embodiments, patients have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or are double-refractory to a PI and an immunomodulatory agent. [180] In some embodiments, patients are newly diagnosed and are ineligible for autologous stem cell transplant or have relapsed or refractory multiple myeloma and have received at least one prior therapy. For some of these patients, a combination therapy includes lenalidomide and dexamethasone. For some of these patients, a combination therapy includes bortezomib, melphalan, and prednisone. For some of these patients, a combination therapy includes bortezomib, thalidomide, and dexamethasone. [181] In some embodiments, patients have received at least one prior therapy. For some of these patients, combination therapy for these patients includes bortezomib and dexamethasone in patients who have received at least one prior therapy. [182] In some embodiments, patients have relapsed or refractory multiple myeloma and have received one to three prior lines of therapy. Combination therapy for these patients includes carfilzomib and dexamethasone. [183] In some embodiments, patients have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Combination therapy for these patients includes pomalidomide and dexamethasone. [184] The dose of belantamab mafodotin administered as part of any of the combination therapies described above can be, for example, 0.5 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg, typically administered as an intravenous infusion every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In some embodiments, a dose of 1.0 mg/kg of belantamab mafodotin is administered every 3 or 4 weeks. In other embodiments, a dose of 1.4 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. In other embodiments, a dose of 1.9 mg/kg of belantamab mafodotin is administered every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks. [185] Independently, the dose of nirogacestat administered as part of any of the combination therapies described above can be, for example, at least about 50, 100, 150, 200, or 250 mg, administered once or twice daily. In some embodiments, 100 mg of nirogacestat is administered twice a day. Kits [186] A kit-of-parts comprising a pharmaceutical composition together with instructions for use is further provided. For convenience, the kit-of-parts may comprise reagents in predetermined amounts with instructions for use. [187] In some embodiments, disclosed herein are kits comprising the combination therapy disclosed herein. A kit may include a plurality of syringes, ampules, foil packets, or blister packs, each containing a single unit dose of a kit component described herein. Containers of a kit may be airtight, waterproof (e.g., impermeable to changes in moisture or evaporation), and/or light-tight. A kit may include a device suitable for administration of the component, e.g., a syringe, inhalant, pipette, forceps, measured spoon, dropper (e.g., eye dropper), swab (e.g., a cotton swab or wooden swab), or any such delivery device. In some embodiments, the device may be a medical implant device, e.g., packaged for surgical insertion. A kit disclosed herein may comprise one or more reagents or instruments which enable the method to be carried out. [188] In addition to the above components, instructions for use may be provided in a kit. These instructions may be present in the kit in a variety of forms, such as printed information on a suitable medium or substrate (e.g., a piece or pieces of paper on which the information is printed), in the packaging of the kit, in a package insert, etc. In some embodiments, instructions for use can be provided on a computer readable medium (e.g., jump/thumb drive, CD, etc.), on which the information has been recorded or at a website address which may be used via the internet to access the information at a website. Devices [189] Another aspect of the present disclosure provides a pre-filled syringe or autoinjector device, comprising the combination therapy described herein. In some embodiments, a combination is stored in a container, pre-filled syringe, injector or autoinjector device. [190] Those skilled in the art will appreciate that there are numerous variations and permutations of the above described embodiments that fall within the scope of the appended claims. EXAMPLES Example 1 [191] A patient suffering from a cancer selected from the group consisting of multiple myeloma, plasma cell myeloma, plasmablastic lymphoma, and anaplastic lymphoma kinase positive large B- cell lymphoma, chronic lymphocytic leukemia, Waldenström macroglobulineamia, and Non- Hodgkin’s lymphoma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; and (c) a therapeutically effective dose of at least one additional active agent selected from the group consisting of (i) an immunomodulatory imide drug (IMiD), (ii) an anti-CD38 antibody, and (iii) a proteasome inhibitor. The combination therapy includes 0.5 mg/kg, 0.95 mg/kg, 1.0 mg/kg, 1.25 mg/kg, 1.4 mg/kg, 1.7 mg/kg, 1.9 mg/kg, 1.92 mg/kg, 2.5 mg/kg, 3.4 mg/kg, or 4.6 mg/kg of belantamab mafodotin. The combination therapy includes at least about 50, 100, 150, 200, or 250 mg of nirogacestat. The combination therapy optionally includes (a) administering to the individual 4 mg of pomalidomide once daily on days 1 through 21 of a repeated 28-day cycle; and (b) administering to the individual 40 mg of dexamethasone on days 1, 8, 15, and 22 of the repeated 28-day cycle. The treatment cycle continues on a weekly basis or every 3 weeks, every 4 weeks, every 6 weeks, or every 8 weeks, depending on the specific needs of the patient. [192] The patient administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues. Example 2 [193] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 0.5 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering lenalidomide, an IMiD, orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [194] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 0.5 mg/kg on day 1 of repeated 28-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) administering lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 of repeated 28-day cycles or (ii) 10 mg on each of days 1 to 21 of repeated 28-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [195] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 3 [196] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering lenalidomide, an IMiD, orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [197] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 56-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) administering lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [198] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 4 [199] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering lenalidomide, an IMiD, orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [200] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 84-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) administering lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [201] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 5 [202] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering lenalidomide, an IMiD, orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [203] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) administering lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles or (ii) 10 mg on each of days 1 to 21 and days 29 to 49 of repeated 56-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [204] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 6 [205] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering lenalidomide, an ImiD, orally to the individual at a dose of (i) 25 mg on each of days 1 to 21 of an initial 28-day cycle or (ii) 10 mg on each of days 1 to 21 of an initial 28-day cycle if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [206] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) administering lenalidomide orally at a dose of (i) 25 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles or (ii) 10 mg on each of days 1 to 21, days 29 to 49, and days 57 to 77 of repeated 84-day cycles if the individual has an estimated glomerular filtration rate (eGFR) of 40-60 mL/min/1.73 m ² ; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [207] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 7 [208] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 0.5 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering pomalidomide, an IMiD, orally to the individual at a dose of 4 mg on each of days 1 to 21 an initial 28-day cycle; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [209] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 0.5 mg/kg on day 1 of repeated 28-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) administering pomalidomide orally at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [210] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 8 [211] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering pomalidomide, an IMiD, orally to the individual at a dose of 4 mg on each of days 1 to 21 an initial 28-day cycle; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [212] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 28-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) administering pomalidomide orally at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [213] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 9 [214] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering pomalidomide, an IMiD, orally to the individual at a dose of 4 mg on each of days 1 to 21 an initial 28-day cycle; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [215] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 28-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 28-day cycles; (c) administering pomalidomide orally at a dose of 4 mg on each of days 1 to 21 of repeated 28-day cycles; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles or (ii) 20 mg on each of days 1, 8, 15, and 22 of repeated 28-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [216] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 10 [217] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering pomalidomide, an IMiD, orally to the individual at a dose of 4 mg on each of days 1 to 21 an initial 28-day cycle; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [218] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 56-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) administering pomalidomide orally at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [219] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 11 [220] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering pomalidomide, an IMiD, orally to the individual at a dose of 4 mg on each of days 1 to 21 an initial 28-day cycle; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [221] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 56-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 56-day cycles; (c) administering pomalidomide orally at a dose of 4 mg on each of days 1 to 21 and days 29 to 50 of repeated 56-day cycles; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, and 50 of repeated 56-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [222] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 12 [223] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.0 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering pomalidomide, an IMiD, orally to the individual at a dose of 4 mg on each of days 1 to 21 an initial 28-day cycle; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [224] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.0 mg/kg on day 1 of repeated 84-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) administering pomalidomide orally at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [225] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 13 [226] An individual suffering from multiple myeloma is administered a combination therapy comprising: a therapeutically effective dose of belantamab mafodotin; (b) a therapeutically effective dose of nirogacestat; (c) a therapeutically effective dose of an immunomodulatory imide drug (IMiD); and (d) a therapeutically effective dose of a corticosteroid. The combination therapy includes belantamab mafodotin administered intravenously to the individual at a dose of 1.4 mg/kg on day 1 of an initial 28-day cycle. The combination therapy includes nirogacestat administered orally to the individual at a dose of 100 mg twice daily on each of days -2 to 28 of an initial 28 day cycle. The combination therapy additionally includes (a) administering pomalidomide, an IMiD, orally to the individual at a dose of 4 mg on each of days 1 to 21 an initial 28-day cycle; and (b) administering dexamethasone, a corticosteroid, orally or intravenously to the individual at a dose of (i) 40 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle or (ii) 20 mg on each of days 1, 8, 15, and 22 of an initial 28-day cycle if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [227] After the initial 28-day cycle, the combination therapy further includes (a) administering belantamab mafodotin intravenously at a dose of 1.4 mg/kg on day 1 of repeated 84-day cycles; (b) administering nirogacestat orally at a dose of 100 mg twice daily on each of days 1 to 28 of repeated 84-day cycles; (c) administering pomalidomide orally at a dose of 4 mg on each of days 1 to 21, days 29 to 50, and days 57 to 77 of repeated 84-day cycles; and (d) administering dexamethasone orally or intravenously at a dose of (i) 40 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles or (ii) 20 mg on each of days 1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, and 78 of repeated 84-day cycles if the individual is older than 75 years or has a body mass index (BMI) of <18.5 kg/m ² . [228] The patient or individual administered the combination therapy described herein exhibits reduced ocular toxicity than would be observed in a patient receiving the therapeutically effective amount of belantamab mafodotin alone. The ocular toxicity is selected from the group consisting of a change in corneal epithelium, dry eyes, irritation, redness, blurred vision, photophobia, and changes in visual acuity and is measured using standard techniques that are well known in the art. Resolution of the toxicity or reduced risk of occurrence of the toxicity persists for as long as the combination therapy continues or for a period of time after the combination therapy is no longer administered to the patient or individual. Example 14 [229] A Phase 1/2 study was conducted to evaluate the efficacy and safety of low-dose belantamab mafodotin (belamaf) plus nirogacestat (niro) vs belamaf alone in triple-class refractory patients with relapsed/refractory multiple myeloma (RRMM). [230] Patients were randomized (1:1) to belamaf 0.95 mg/kg Q3W (low-dose) + niro 100 mg BID or belamaf 2.5 mg/kg Q3W monotherapy. The primary objective was to assess the clinical activity (overall response rate; ORR) of low-dose belamaf + niro combination in comparison with the monotherapy control arm. [231] Data from 34 patients treated with low-dose belamaf + niro and 37 patients treated with belamaf monotherapy are presented in Table 2. Patients had a median (range) age of 68 (48–81) years and a median of 5 (3–14) prior lines of therapy. Patients received a median of 4 (1–20) cycles of the combination and 3 (1–9) monotherapy cycles. The ORR was 28% (95% CI 15.1, 47.5) and 39% (22.5, 55.2) for the combination and monotherapy arms, respectively. Median (IQR) time to response was 1.1 (0.7, 1.5) and 1.5 (0.8, 2.1) months. Incidence of ≥Grade 3 adverse events (AEs) was similar between arms (76% combination vs 65% monotherapy); Grade 3 ocular events were less frequent for low-dose belamaf + niro (29% vs 59%). No Grade 4 or higher ocular events or new toxicities were identified. Four patients discontinued study treatment (combination n=3; monotherapy n=1) due to AEs unrelated to study treatment. Table 2 *Incorporating prior ORR for low-dose belamaf + niro from DREAMM-5 SS3 Dose Exploration cohort (observed ORR 60% (6/10)) and from DREAMM-2 monotherapy (observed ORR 31% (30/97)).